Literature DB >> 17115388

Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study.

Jaime Kulisevsky1, Berta Pascual-Sedano, Manel Barbanoj, Alexandre Gironell, Javier Pagonabarraga, Carmen García-Sánchez.   

Abstract

Mood fluctuations related to levodopa (LD) dosing are well-known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing-off) and to different pharmacokinetic profiles of oral LD. We used an intrasubject randomized double-blind crossover design to study 14 patients (7 stable, 7 wearing-off) who were monitored for motor status, mood, anxiety, and plasma LD levels 1 hour before and 6 hours after an oral dose of immediate-release (IR) and controlled-release LD formulations. Analysis of the dose-response curves showed a significant interaction between the type of motor response and the type of LD. Only the wearing-off patients had a significant mood elevation, and this effect was only significant following challenge with IR LD. Motor status strongly correlated with LD plasma levels and anxiety but not with mood ratings. Mood changes in PD patients are related to the patient's type of motor response to oral LD and also to the kinetic profile of the LD formulation used for dopaminergic replacement. Copyright 2006 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17115388     DOI: 10.1002/mds.21205

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

Review 1.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 2.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

3.  [Coexistent depressive and anxiety disorders in neurological diseases: from a perspective of multimorbidity].

Authors:  H P Kapfhammer
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

4.  Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic L-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells.

Authors:  Zhaofei Yang; Xuan Wang; Jian Yang; Min Sun; Yong Wang; Xiaomin Wang
Journal:  Neurotox Res       Date:  2016-12-15       Impact factor: 3.911

5.  Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.

Authors:  Karen L Eskow Jaunarajs; Kristin B Dupre; Corinne Y Ostock; Thomas Button; Terrence Deak; Christopher Bishop
Journal:  Behav Pharmacol       Date:  2010-10       Impact factor: 2.293

6.  Anxiety and self-perceived health status in Parkinson's disease.

Authors:  Gregory M Pontone; James R Williams; Karen E Anderson; Gary Chase; Susanne R Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Peter V Rabins; Howard D Weiss; Laura Marsh
Journal:  Parkinsonism Relat Disord       Date:  2011-02-02       Impact factor: 4.891

7.  L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.

Authors:  K L Eskow Jaunarajs; J A George; C Bishop
Journal:  Neuroscience       Date:  2012-06-01       Impact factor: 3.590

Review 8.  The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

Authors:  Daniel Weintraub; Eugenia Mamikonyan
Journal:  Am J Geriatr Psychiatry       Date:  2019-03-09       Impact factor: 4.105

9.  Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS).

Authors:  Alexander Storch; Christine B Schneider; Lisa Klingelhöfer; Per Odin; Gerd Fuchs; Wolfgang H Jost; Pablo Martinez-Martin; Rainer Koch; Heinz Reichmann; K Ray Chaudhuri; Georg Ebersbach
Journal:  J Neural Transm (Vienna)       Date:  2015-08-12       Impact factor: 3.575

Review 10.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.